LL-37 vs Thymosin Alpha-1

What Are LL-37 and Thymosin Alpha-1?

LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.

Thymosin Alpha-1 (Thymosin alpha 1 (28-amino acid peptide)) is a Thymic peptide, immunomodulator. Naturally occurring peptide isolated from thymus gland; synthetic form (thymalfasin/Zadaxin) developed for immune enhancement. It is researched for immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do LL-37 and Thymosin Alpha-1 Work Differently?

LL-37 mechanism: Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bacterial cells, and disrupts biofilms and viral envelopes. Also immunomodulatory — activates chemokine receptors and enhances inflammatory response. Effective against 38+ bacteria, 16 fungi, and 16 viruses.

Thymosin Alpha-1 mechanism: Engages Toll-like receptors (TLR) on myeloid and plasmacytoid dendritic cells, triggering MyD88-dependent signaling cascades. Drives IL-2 production, IFN-gamma stimulation, and T lymphocyte/NK cell activation while promoting thymopoiesis. Simultaneously suppresses pro-inflammatory IL-6/TNF-alpha while enhancing anti-inflammatory IL-10.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

LL-37: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Half-life: rapidly degraded by proteases; major clinical limitation. Cycle: acute use as needed.

Thymosin Alpha-1: 1.6-6.4 mg per dose administered twice weekly via subcutaneous injection. Half-life: not established. Cycle: 5-7 day injection cycles, repeated as needed.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

LL-37 benefits: broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.

Thymosin Alpha-1 benefits: immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

LL-37: Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.

Thymosin Alpha-1: Well-tolerated. Local injection site reactions most common. Safe in liver disease, cancer, and autoimmune conditions. No significant organ toxicity.

Can You Stack LL-37 and Thymosin Alpha-1 Together?

Many researchers combine LL-37 and Thymosin Alpha-1 in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair. See our stacking guide for general principles.

Which Is Better: LL-37 or Thymosin Alpha-1?

There is no universal answer. LL-37 may be preferable for researchers focused on broad-spectrum antimicrobial activity, while Thymosin Alpha-1 is stronger for immune activation.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: LL-37 | Thymosin Alpha-1.

Frequently Asked Questions